Brain metastases from primary colorectal cancer: is radiosurgery an effective treatment approach? Results of a multicenter study of the radiation and clinical oncology Italian association (AIRO).
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
01 Dec 2020
01 Dec 2020
Historique:
pubmed:
10
10
2020
medline:
15
12
2020
entrez:
9
10
2020
Statut:
ppublish
Résumé
The prognosis of brain metastatic colorectal cancer patients (BMCRC) is poor. Several local treatments have been used, but the optimal treatment choice remains an unresolved issue. We evaluated the clinical outcomes of a large series of BMCRC patients treated in several Italian centers using stereotactic radiosurgery (SRS). 185 BMCRC patients for a total of 262 lesions treated were evaluated. Treatments included surgery followed by post-operative SRS to the resection cavity, and SRS, either single-fraction, then hypofractionated SRS (HSRS). Outcomes was measured in terms of local control (LC), toxicities, brain distant failure (BDF), and overall survival (OS). Prognostic factors influencing survival were assed too. The median follow-up time was 33 months (range 3-183 months). Surgery plus SRS have been performed in 28 (10.7%) cases, SRS in 141 (53.8%), and HSRS in 93 (35.5%). 77 (41.6%) patients received systemic therapy. The main total dose and fractionation used were 24 Gy in single fraction or 24 Gy in three daily fractions. Local recurrence occurred in 32 (17.3%) patients. Median, 6 months,1-year-LC were 86 months (95%CI 36-86), 87.2% ± 2.8, 77.8% ± 4.1. Median,6 months,1-year-BDF were 23 months (95%CI 9-44), 66.4% ± 3.9, 55.3% ± 4.5. Median,6 months,1-year-OS were 7 months (95% CI 6-9), 52.7% ± 3.6, 33% ± 3.5. No severe neurological toxicity occurred. Stage at diagnosis, Karnofsky Performance Status (KPS), presence and number of extracranial metastases, and disease-specific-graded-prognostic-assessment (DS-GPA) score were observed as conditioning survival. SRS/HSRS have proven to be an effective local treatment for BMCRC. A careful evaluation of prognostic factors as well as a multidisciplinary evaluation is a valid aid to manage the optimal therapeutic strategy for CTC patients with BMs. The prognosis of BMCRC is poor. Several local treatments was used, but optimal treatment choice remains undefined. Radiosurgery has proven to be an effective local treatment for BMCRC. A careful evaluation of prognostic factors and a multidisciplinary evaluation needed.
Identifiants
pubmed: 33035077
doi: 10.1259/bjr.20200951
pmc: PMC7716018
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
20200951Références
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
J Gastrointest Oncol. 2017 Feb;8(1):55-63
pubmed: 28280609
Am J Gastroenterol. 2016 Mar;111(3):355-65
pubmed: 26753884
BMC Cancer. 2015 Nov 16;15:902
pubmed: 26572484
Cancer. 1999 Apr 15;85(8):1677-85
pubmed: 10223560
J Gastrointest Oncol. 2015 Dec;6(6):645-9
pubmed: 26697197
Cancer. 2009 Feb 15;115(4):890-8
pubmed: 19132728
Dis Colon Rectum. 2014 Jan;57(1):56-63
pubmed: 24316946
Clin Colorectal Cancer. 2011 Jun;10(2):121-5
pubmed: 21859565
Colorectal Dis. 2012 Jul;14(7):e378-85
pubmed: 22288509
Int J Mol Sci. 2012 Nov 26;13(12):15784-800
pubmed: 23443093
Int J Colorectal Dis. 2018 Nov;33(11):1517-1523
pubmed: 29943356
ANZ J Surg. 2018 Mar;88(3):140-145
pubmed: 28687024
Cancer Radiother. 2017 May;21(3):199-204
pubmed: 28499660
J Neurosurg. 2011 Mar;114(3):782-9
pubmed: 20950083
Tumour Biol. 2011 Dec;32(6):1249-56
pubmed: 21913132
Radiat Oncol. 2016 Jun 02;11:76
pubmed: 27249940
Oncotarget. 2015 Nov 17;6(36):38658-66
pubmed: 26484417
JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
J Cancer Res Clin Oncol. 2009 Mar;135(3):451-7
pubmed: 18779977
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
Int J Colorectal Dis. 2002 May;17(3):150-5
pubmed: 12049308
J Clin Neurosci. 2013 Oct;20(10):1417-21
pubmed: 23910824
N Y State J Med. 1982 Dec;82(13):1812-4
pubmed: 6961303
Med Oncol. 2014 Sep;31(9):152
pubmed: 25108599
World J Surg. 2009 Apr;33(4):817-21
pubmed: 19194739
Curr Oncol. 2012 Oct;19(5):254-8
pubmed: 23144573
BMC Cancer. 2016 Apr 01;16:260
pubmed: 27037031
J Neurooncol. 2011 Sep;104(3):745-53
pubmed: 21336772
Oncology. 2017;93(5):309-314
pubmed: 28700994
Cancer. 2015 Apr 15;121(8):1195-203
pubmed: 25491172
Cancer. 2008 Jul 1;113(1):158-65
pubmed: 18459179
Anticancer Res. 2013 Dec;33(12):5645-8
pubmed: 24324111
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Clin Colorectal Cancer. 2015 Dec;14(4):281-90
pubmed: 26123495
Clin Colorectal Cancer. 2009 Mar;8(2):100-5
pubmed: 19423503
J Surg Oncol. 2012 Aug 1;106(2):144-8
pubmed: 22287384
J Neurooncol. 2014 Nov;120(2):339-46
pubmed: 25059451